Pingzheng Mo1, Qi Zhu2, Caroline Teter3, Rongrong Yang1, Liping Deng1, Yajun Yan1, Jun Chen2, Jie Zeng2, Xi-en Gui4. 1. Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China. 2. Wuhan Tuberculosis Control Center, Hubei, China. 3. Project HOPE, Millwood, Virginia, USA. 4. Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China. Electronic address: ZNACT@126.com.
Abstract
OBJECTIVES: To investigate the prevalence, incidence of abnormal liver function tests (LFTs), and mortality during anti-TB treatment in patients multi-infected with HIV, tuberculosis (TB), and hepatitis virus (hepatitis B virus (HBV) and hepatitis C virus (HCV)). METHODS: Three hundred and sixty-one HIV-positive TB patients were enrolled and divided into an HIV/TB group, HIV/TB/HBV group, and HIV/TB/HCV group; 1013 HIV-negative TB patients were selected randomly as controls. RESULTS: One hundred and seventeen (32.4%) HIV-positive TB patients were infected with HBV and/or HCV, compared with 90 (8.9%) HIV-negative TB patients (p=0.000). HIV-positive TB patients had a higher incidence of anti-TB drug-induced hepatotoxicity than HIV-negative TB patients (4.2% vs. 1.0%, odds ratio (OR) 4.348, 95% confidence interval (CI) 1.935-9.769, p=0.000). The incidence of abnormal LFTs in the HIV/TB/HBV group and HIV/TB/HCV group were significantly higher than in the HIV/TB group (40.7% vs. 11.1%, OR 5.525, 95% CI 2.325-13.131, p=0.000; 20.0% vs. 11.1%, OR 2.009, 95% CI 1.057-3.820, p=0.031). A total of 68.4% of patients with HBV-DNA >1.0×10(5) copies/ml and 42.9% of patients with HCV-RNA >1.0×10(5) copies/ml had abnormal LFTs. Twenty-three (19.7%) patients multi-infected with HIV, TB, and hepatitis virus died during anti-TB treatment. CONCLUSIONS: HIV, HBV, and HCV are risk factors for the development of abnormal LFTs and mortality during anti-TB treatment. TB patients co-infected with HIV and hepatitis virus need close follow-up.
OBJECTIVES: To investigate the prevalence, incidence of abnormal liver function tests (LFTs), and mortality during anti-TB treatment in patientsmulti-infected with HIV, tuberculosis (TB), and hepatitis virus (hepatitis B virus (HBV) and hepatitis C virus (HCV)). METHODS: Three hundred and sixty-one HIV-positive TB patients were enrolled and divided into an HIV/TB group, HIV/TB/HBV group, and HIV/TB/HCV group; 1013 HIV-negative TB patients were selected randomly as controls. RESULTS: One hundred and seventeen (32.4%) HIV-positive TB patients were infected with HBV and/or HCV, compared with 90 (8.9%) HIV-negative TB patients (p=0.000). HIV-positive TB patients had a higher incidence of anti-TB drug-induced hepatotoxicity than HIV-negative TB patients (4.2% vs. 1.0%, odds ratio (OR) 4.348, 95% confidence interval (CI) 1.935-9.769, p=0.000). The incidence of abnormal LFTs in the HIV/TB/HBV group and HIV/TB/HCV group were significantly higher than in the HIV/TB group (40.7% vs. 11.1%, OR 5.525, 95% CI 2.325-13.131, p=0.000; 20.0% vs. 11.1%, OR 2.009, 95% CI 1.057-3.820, p=0.031). A total of 68.4% of patients with HBV-DNA >1.0×10(5) copies/ml and 42.9% of patients with HCV-RNA >1.0×10(5) copies/ml had abnormal LFTs. Twenty-three (19.7%) patientsmulti-infected with HIV, TB, and hepatitis virus died during anti-TB treatment. CONCLUSIONS: HIV, HBV, and HCV are risk factors for the development of abnormal LFTs and mortality during anti-TB treatment. TB patients co-infected with HIV and hepatitis virus need close follow-up.
Entities:
Keywords:
HIV; Hepatitis B virus; Hepatitis C virus; Tuberculosis
Authors: Cintia Costi; Tarciana Grandi; Maria Laura Halon; Márcia Susana Nunes Silva; Cláudia Maria Dornelles da Silva; Tatiana Schäffer Gregianini; Lia Gonçalves Possuelo; Carla Adriane Jarczewski; Christian Niel; Maria Lucia Rosa Rossetti Journal: Mem Inst Oswaldo Cruz Date: 2017-04 Impact factor: 2.743
Authors: Mohamed Ahmed El-Mokhtar; Sherein G Elgendy; Abeer Sharaf Eldin; Elham Ahmed Hassan; Ali Abdel Azeem Hasan; Muhamad R Abdel Hameed; Douaa Sayed; Eman H Salama Journal: Viruses Date: 2020-01-15 Impact factor: 5.048